Neo Ivy Capital Management Fibrogen Inc Transaction History

Neo Ivy Capital Management

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 16, 2021	SELL	$10.18 - $26.64 $40,068 - $104,855	-3,936 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$18.57 - $35.68 $68,337 - $131,302	3,680 Added 1437.5%	3,936 $105,000
Q1 2021 Oct 07, 2021	SELL	$31.0 - $55.72 $185,101 - $332,704	-5,971 Reduced 95.89%	256 $9,000
Q4 2020 Feb 16, 2021	BUY	$37.09 - $48.97 $80,077 - $105,726	2,159 Added 53.07%	6,227 $231,000
Q3 2020 Nov 17, 2020	SELL	$40.47 - $45.5 $868,931 - $976,930	-21,471 Reduced 84.07%	4,068 $167,000
Q2 2020 Aug 17, 2020	BUY	$32.57 - $42.83 $831,805 - $1.09 Million	25,539 New	25,539 $1.04 Million
Q1 2020 May 15, 2020	SELL	$23.3 - $45.96 $16,333 - $32,217	-701 Closed	0 $0
Q4 2019 Feb 13, 2020	BUY	$34.58 - $48.06 $24,240 - $33,690	701 New	701 $30,000
Q3 2019 Nov 21, 2019	SELL	$36.98 - $48.45 $944,432 - $1.24 Million	-25,539 Closed	0 $0
Q2 2019 Aug 15, 2019	BUY	$35.13 - $55.53 $897,185 - $1.42 Million	25,539 New	25,539 $1.15 Million
Q1 2019 May 15, 2019	SELL	$42.83 - $59.91 $754,279 - $1.06 Million	-17,611 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$37.97 - $60.16 $668,689 - $1.06 Million	17,611 New	17,611 $815,000

37.3M

351K

105K

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $31.9M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

Get notified when there are updates to the investment portfolio of Neo Ivy Capital Management, based on Form 13F filings with the SEC.

Stay updated on Neo Ivy Capital Management with notifications on news.